BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
- Overview
- Agencies
- Programs
- Recipients
- Awards
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

Overview Firms Clients Revolving Door Stands Out

LD-2 disclosure · 4th Quarter - Termination

GLOBAL BLOOD THERAPEUTICS

via NVG, LLC

4th Quarter (Oct 1 - Dec 31) · 2022Posted Apr 11, 2023Filing document ↗LDA record ↗

Income$50Kfee reported

Client

Name: GLOBAL BLOOD THERAPEUTICS
Description: Bio pharmaceutical company
Location: California · United States of America

Registrant

Firm: NVG, LLC
Description: Government Relations Firm
Location: Washington, District of Columbia, United States of America

Lobbying activities

1 issue

Health Issues
H.R.8855/S.4866 - Sickle Cell Disease Treatment Centers Act of 2022.
LobbyistsIRENE BUENO · ms LISA GERMAN FOSTER · EDEN SHIFERAW
TargetedSENATE · Health & Human Services, Dept of (HHS)

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.

GLOBAL BLOOD THERAPEUTICS — Lobbying — Receipts Report